V-domain Ig-containing suppressor of T cell activation (VISTA) is a unique immune checkpoint protein, which was reported to display both receptor and ligand activities. However, the mechanisms of regulation of VISTA activity and functions by factors of tumour microenvironment (TME) remain unclear and understanding these processes is required in order to develop successful personalised cancer immunotherapeutic strategies and approaches. Here we report for the very first time that VISTA interacts with another immune checkpoint protein galectin-9 inside the cell most likely facilitating its interaction with TGF-β-activated kinase 1 (TAK1). This process is required for protection of lysosomes, which is crucial for many cell types and tissues. We found that VISTA expression can be differentially controlled by crucial factors present in TME, such as transforming growth factor beta type 1 (TGF-β) and hypoxia as well as other factors activating hypoxic signalling. We confirmed that involvement of these important pathways modulated by TME differentially influences VISTA expression in different cell types. These networks include: TGF-β-Smad3 pathway, TAK1 (TGF-β-activated kinase 1) or apoptosis signal-regulating kinase 1 (ASK1)-induced activation of activating transcription factor 2 (ATF-2) and hypoxic signalling pathway. Based on this work we determined the five critical functions of VISTA and the role of TME factors in controlling (modulating or downregulating) VISTA expression.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2025.217581DOI Listing

Publication Analysis

Top Keywords

vista expression
12
v-domain ig-containing
8
ig-containing suppressor
8
suppressor cell
8
cell activation
8
vista
8
activation vista
8
factors tumour
8
tumour microenvironment
8
immune checkpoint
8

Similar Publications

The opioid crisis has highlighted the urgent need for alternative pain management strategies. This review explores novel non-opioid targets and pathways involved in pain modulation, highlighting advancements in understanding and therapeutic potential. Pain, a multifaceted phenomenon with nociceptive, neuropathic, and inflammatory components, involves intricate molecular signaling cascades.

View Article and Find Full Text PDF

Analysis and Transcriptional Profiling of A Putative Metalloprotease ADAMTSL as A Potential Tick Antigen against .

Pathogens

February 2025

Centro Nacional de Investigación Disciplinaria en Salud Animal e Inocuidad-INIFAP, Carretera Federal Cuernavaca-Cuautla 8534, Col. Progreso, Jiutepec 62550, Mexico.

The cattle tick, , is the most significant ectoparasite in the cattle industry. The application of acaricides constitutes the main control method. However, inadequate treatments have serious drawbacks, including the appearance of multi-resistant ticks.

View Article and Find Full Text PDF

Pancreatic ductal adenocarcinoma (PDAC) poses a significant challenge due to late-stage diagnoses. To improve patient outcomes, early intervention in precursor lesions such as intraductal papillary mucinous neoplasm (IPMN) is crucial. However, early intervention must be balanced against overtreatment of low-risk lesions that are unlikely to progress, underscoring the need to better understand molecular alterations in neoplastic cells and changes in the tumor microenvironment (TME) that drive the progression of IPMNs.

View Article and Find Full Text PDF

Cutaneous squamous cell carcinoma (cSCC) is one of the most common human cancers whose estimated deaths approach or exceed that of melanoma. Immune inhibitory receptor antagonism through blockade of programmed death receptor 1 (PD-1) or its ligand PD-L1, has revolutionized the treatment of cSCC; however, approximately half of the patients still fail to respond. Inhibitory receptor programmed death-1 homolog (PD-1H) (also known as VISTA) functions to control T cell and myeloid cell functions in pre-clinical cancer studies.

View Article and Find Full Text PDF

V-domain Ig-containing suppressor of T cell activation (VISTA) is a unique immune checkpoint protein, which was reported to display both receptor and ligand activities. However, the mechanisms of regulation of VISTA activity and functions by factors of tumour microenvironment (TME) remain unclear and understanding these processes is required in order to develop successful personalised cancer immunotherapeutic strategies and approaches. Here we report for the very first time that VISTA interacts with another immune checkpoint protein galectin-9 inside the cell most likely facilitating its interaction with TGF-β-activated kinase 1 (TAK1).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!